TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02790034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
Study: NCT00548379
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: olive oil 1ml
Study: NCT02658916
Drug: BIIB092
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dose as corresponding CN002003 study panel.
Study: NCT03418857
Drug: Yogurt smoothie
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the one month control period, the participants will consume one yogurt smoothie daily.
Study: NCT02499224
Drug: YYB101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development
Study: NCT04102241
Drug: 15mg Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay005 is a small molecule PDE4 inhibitor.
Study: NCT04102241
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos are the same as drugs, but contain no Hemay005.
Study: NCT03712241
Drug: K-285
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT03712241
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule
Study: NCT01842126
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending Doses intravenous (IV) of Placebo
Study: NCT01842126
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending Doses subcutaneous (SC) of placebo
Study: NCT02106650
Drug: Folotyn and Leucovorin
Normalized name: Folotyn
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02106650
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
Study: NCT02594371
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00070616
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01280617
Drug: Thymoglobulin 0.75mg/kg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin
Study: NCT02290093
Drug: Split-dose full-volume PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
Study: NCT02290093
Drug: Split-dose low-volume PEG
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
Study: NCT02439203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00573170
Drug: TREXIMET®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
Study: NCT00573170
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00733031
Drug: AZD6918
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid suspension, daily, oral dose
Study: NCT03878888
Drug: Exparel 266 MG Per 20 ML Injection
Normalized name: Exparel 266 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive Exparel in bilateral TAP blocks for open abdomen surgery
Study: NCT00964288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match GSK drug and positive control
Study: NCT02199678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00971737
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02224573
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00296491
Drug: placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle placebo nasal spray
Study: NCT00296491
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT00296491
Drug: placebo DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo DISKUS
Study: NCT01934738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, TID or titration, 14 days
Study: NCT02407171
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg every 2 weeks by IV infusion
Study: NCT01546649
Drug: TAP-144-SR(3M)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03645499
Drug: Topical TA-102 C
Normalized name: Xoten-C Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Study: NCT01643226
Drug: placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0% riboflavin ophthalmic solution
Study: NCT03714555
Drug: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
Study: NCT02433119
Drug: CODIOVAN® 160/12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01570348
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01570348
Drug: Mycophenolic Acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02011750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
Study: NCT01907880
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg IV every 4 weeks for 3 cycles
Study: NCT01907880
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03649412
Drug: GSK2982772 Modified Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
Study: NCT03649412
Drug: GSK2982772 Immediate Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
Study: NCT03738527
Drug: Normal Saline Flush, 0.9%, 20mL topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure
Study: NCT01434576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
Study: NCT01849016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00285584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
Study: NCT00567476
Drug: Inhaled corticosteroids (ICS)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
Study: NCT00567476
Drug: Short-acting beta 2-adrenergic agonist (SABA)
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
Study: NCT01128582
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
Study: NCT04272476
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04661826
Drug: Oncofid-P-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
Study: NCT01373060
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01373060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02696031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Study: NCT04403763
Drug: AGN-241622
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eye drop
Study: NCT04403763
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eye drop
Study: NCT04047563
Drug: PMZ-1620 (sovateltide) along with standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study: NCT00749502
Drug: MK-4827
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
Study: NCT03060850
Drug: AC0010MA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
Study: NCT01376310
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 2 mg/day
Study: NCT02187107
Drug: rtv
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet of Norvir®
Study: NCT03913260
Drug: LY3375880
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00711841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
Study: NCT02786719
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CYCLE 1+2 (given by intravenous catheter daily for 5 days)
Study: NCT02786719
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 4+6 (given daily for 2 days)
Study: NCT02786719
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 4+6 (given daily for 3 days)
Study: NCT04688580
Drug: XW10172
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various formulations
Study: NCT00493246
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
Study: NCT00214331
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
Study: NCT00214331
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
Study: NCT00421538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
Study: NCT00754013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally.
Study: NCT02242318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00494624
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01132664
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
Study: NCT01132664
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
Study: NCT01322971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally twice daily for seven days
Study: NCT00892281
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy
Normalized name: doxycycline anhydrous 40 MG [Oracea]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily in the morning
Study: NCT00892281
Drug: doxycycline (Oracea®) 40 mg modified release as add-on therapy
Normalized name: doxycycline anhydrous 40 MG [Oracea]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily in the morning
Study: NCT03716934
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
Study: NCT00004224
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03720574
Drug: Matching Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tablet each morning and evening for a duration of 48 weeks
Study: NCT01049412
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
Study: NCT04189211
Drug: BAT8001
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions.
Study: NCT01364324
Drug: standard first line anti-TB drugs
Normalized name: Standard ANSI First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
Study: NCT02573935
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p.o. clarithromycin 500 mg twice daily for 63 days
Study: NCT02573935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily for 63 days
Study: NCT02573935
Drug: VCD induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
Study: NCT01655524
Drug: ASSUAGE Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
Study: NCT03829358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk containing placebo to be consumed once daily for three weeks.
Study: NCT00742599
Drug: NPO-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml NPO-11
Study: NCT00742599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml NPO-11(Placebo)
Study: NCT02947724
Drug: SURGICEL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
Study: NCT00692224
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
Study: NCT02164734
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: additional premedication in the endotracheal intubation/INSURE arm
Study: NCT00365287
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00272506
Drug: inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00272506
Drug: long-acting beta2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02464826
Drug: Nailprotex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nailprotex apply to the abnormal nail twice daily
Study: NCT00682214
Drug: Lactose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Study: NCT02191475
Drug: Haizheng Li Xing ® plus tazocin ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
Study: NCT01370213
Drug: Preparative Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative Regimen:~1) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,
Study: NCT00287300
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02315547
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
Study: NCT02508402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two milliliters of normal saline given to placebo group .
Study: NCT01763918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03061838
Drug: MabThera®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenously
Study: NCT02122718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03061838
Drug: Ritumax®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenously
Study: NCT01553747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets twice daily
Study: NCT04854252
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
Study: NCT04535752
Drug: ANX009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple ascending dose
Study: NCT04535752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple ascending dose
Study: NCT00472797
Drug: Rebif New Formulation Non Titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: human interferon beta 1a - Rebif New Formulation
Study: NCT00472797
Drug: Rebif New Formulation Titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human interferon beta 1a Rebif New Formulation
Study: NCT00303667
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously (IV) 50 mg/kg on Day -15